Market closedNon-fractional

CytomX/CTMX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About CytomX

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Ticker

CTMX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

South San Francisco, United States

Employees

121

CytomX Metrics

BasicAdvanced
$101M
Market cap
6.07
P/E ratio
$0.21
EPS
1.08
Beta
-
Dividend rate
$101M
1.08
1.157
1.131
-25.72
-40.631
3.23%
-27.95%
6.067
0.842
-2.77
-2.64
-1.086
76.24%
-119.85%
21.32%
-44.06%

What the Analysts think about CytomX

Analyst Ratings

Majority rating from 7 analysts.
Buy

CytomX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
33.09% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$41M
55.64%
Net income
$14M
1,612.50%
Profit margin
33.09%
1,003.00%

CytomX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 305.23%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.02
$0.04
$0.01
$0.17
-
Expected
-$0.21
-$0.19
-$0.03
-$0.08
-$0.14
Surprise
-90.24%
-121.18%
-135.00%
-305.23%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for CytomX stock?

CytomX (CTMX) has a market cap of $101M as of July 06, 2024.

What is the P/E ratio for CytomX stock?

The price to earnings (P/E) ratio for CytomX (CTMX) stock is 6.07 as of July 06, 2024.

Does CytomX stock pay dividends?

No, CytomX (CTMX) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next CytomX dividend payment date?

CytomX (CTMX) stock does not pay dividends to its shareholders.

What is the beta indicator for CytomX?

CytomX (CTMX) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell CytomX stock

Buy or sell CytomX stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing